Great to read about the valuation and numbers.
Despite the novelty of WCK 5222, I have a different opinion regarding the revenue potential. I believe the majority revenue will come from WCK 4873 (Nafithromycin, trademarked as MIQNAF). I did some number crunching myself and in my opinion, Miqnaf will bring in $1.2b per year as compared to $0.5b of Zaynich, at least initially. Beyond the first few years, as @phreakv6 mentioned, WCK 5222 will open up new opportunities, which may tilt the balance in favor of the later. Both are conservative estimates.
Disclosure: Invested.
| Subscribe To Our Free Newsletter |
